For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Hyperlipidemia - Independent medicine & health information for consumers & professionals Hyperlipidemia
Show health professional infoLatest independent information about hyperlipidemia, including medicines and non-drug treatments, written and reviewed by experts in Australia.
Hyperlipidemia is also known as hyperlipidaemia, dyslipidaemia, high cholesterol, hypercholesterolaemia or hyperlipoproteinaemia.
| Filter by audience: | |
|---|---|
| All | |
| Consumer | |
| Health professional | |
| Researchers & evaluators | |
| Members & stakeholders | |
| Other | |
| Title | Description | Type | Audience  |
Date* |
|---|---|---|---|---|
Statins remain important for people at high risk of heart attack or stroke |
NPS is urging people taking statins to continue to take their medicine as prescribed and to see their doctor if they are unsure about the benefit of the medicine for them. |
Media release | Others | 2012-03-01 19:00:00 |
Amlodipine with atorvastatin (Caduet) for dyslipidaemia with concomitant hypertension or angina |
Reviews use of amlodipine/atorvastatin combination for concurrent dyslipidaemia, hypertension, and angina in comparison with use as single agent therapy. |
Professional publication - NPS RADAR - Review | Health Professionals | 2006-12-01 00:00:00 |
Atorvastatin (Lipitor) for the management of lipid disorders |
Reviews use of atorvastatin for hyperlipidaemia, including comparison with simvastatin and pravastatin. Risk of myopathy and rhabdomyolysis is similar to that from other statins. |
Professional publication - NPS RADAR - Review | Health Professionals | 2005-12-01 00:00:00 |
Case study 19 report: Dyslipidaemia and coronary heart disease risk |
Patient identified as having elevated cholesterol levels at routine health check up. He is an overweight smoker who doesn't exercise regularly. Family history of cardiovascular disease. |
Professional activity - Case study report | Health Professionals | 2002-02-01 00:00:00 |
Case study 19: Dyslipidaemia and coronary heart disease risk |
Patient identified as having elevated cholesterol levels at routine health check up. He is an overweight smoker who doesn't exercise regularly. Family history of cardiovascular disease. |
Professional activity - Case study | Health Professionals | 2002-02-01 00:00:00 |
Case study 67: CVD risk: guiding lipid management |
Ric is a 49-year-old IT consultant who has come to see you concerned that he is at risk of a heart attack |
Professional publication - NPS News | Health Professionals | 2011-02-01 00:00:00 |
Case study PH5 report. For pharmacists. Dyslipidaemia and coronary heart disease risk |
Female patient presents her first prescription for simvastatin. She doesn't really want to take it and asks you if she should bother. |
Professional activity - Case study report | Health Professionals | 2002-02-01 00:00:00 |
Case study PH5. For pharmacists. Dyslipidaemia and coronary heart disease risk |
Female patient presents her first prescription for simvastatin. She doesn't really want to take it and asks you if she should bother. |
Professional activity - Case study | Health Professionals | 2002-02-01 00:00:00 |
Articles on dyslipidaemia drugs from NPS RADAR |
Get independent, evidence-based info on dyslipidaemia drugs. Written for doctors, pharmacists & other health professionals. |
Topic overview | Health Professionals | 2009-10-28 00:00:00 |
Dyslipidaemia drugs |
Accurate, balanced, evidence-based information, resources & educational activities on dyslipidaemia drugs. Information for health professionals. |
Topic overview | Health Professionals | 2009-09-20 00:00:00 |
Dyslipidaemia treatments a focus of NPS RADAR |
Media release noting that the March 2006 edition of NPS RADAR discusses the combined ezetimibe and simvastatin tablet (Vytorin) and reviews the results of an Australian trial of fenofibrate. |
Media release | Others | 2006-03-01 00:00:00 |
Ezetimibe (Ezetrol) for dyslipidaemia |
Reviews use of ezetimibe for dyslipidaemia as an alternative to statins or in combination with other statins. |
Professional publication - NPS RADAR - Review | Health Professionals | 2004-08-01 00:00:00 |
Ezetimibe with simvastatin (Vytorin) |
Ezetimibe with simvastatin (Vytorin) for dyslipidaemia |
Professional publication - NPS RADAR - Review | Health Professionals | 2006-03-01 00:00:00 |
Fenofibrate (Lipidil) for dyslipidaemia |
Reviews use of fenofibrate for dyslipidaemia, including comparison with gemfibrozil and monitoring for myopathy when used in combination with a statin. |
Professional publication - NPS RADAR - Review | Health Professionals | 2006-02-01 00:00:00 |
Find out your risk score before it’s game over |
Australians should pay as much attention to their heart and stroke risk score as the footy score this autumn, according to NPS MedicineWise, which has launched a new campaign focusing on cardiovascular disease |
Media release | Others | 2011-04-11 19:00:00 |
Keep taking your statins: benefits outweigh risks |
Recent media reports suggest statin medicines increase the risk of diabetes & memory loss in patients. However, research shows that the benefits of statins outweigh the risks & NPS is advising people to keep taking their statin medicines, unless their doctor says otherwise. Read more on the risks & benefits of statins here |
Web page | Consumers | 2012-03-01 00:00:00 |
Clinical e-Audit: Lipids |
Clinical e-audit to help GPs review their management of patients who are at risk of CVD and may benefit from lipid-modifying therapy |
Professional activity - Clinical audit | Health Professionals | 2010-07-01 00:00:00 |
Neither new nor breakthrough: NPS RADAR on Vytorin |
The latest edition of NPS RADAR reviews the medicine ezetimibe (Ezetrol) and a fixed-dose combined ezetimibe and simvastatin tablet (Vytorin) used to treat high cholesterol. |
Media release | Others | 2006-03-31 00:00:00 |
Lipid management and CHD risk |
Examines absolute risk and relative risk assessments for coronary heart disease, impact on management and lipid-modifying therapy |
Professional publication - NPS News | Health Professionals | 2002-02-01 00:00:00 |
Managing lipids -Reducing CVD risk |
Outlines tools for identifying people at increased cardiovascular risk and strategies to help people stay on effective treatment. Many could benefit from a lipid-modifying drug but are not being treated. |
Professional publication - NPS News | Health Professionals | 2011-02-01 00:00:00 |
NPS Prescribing Practice Review 17: Managing dyslipidaemia |
Information on managing dyslipidaemia, including who should be treated with lipid-modifying therapy (i.e. lifestyle and/or drug therapy). Sample feedback prescribing data is also provided. |
Professional publication - Prescribing Practice Review | Health Professionals | 2002-03-05 00:00:00 |
Managing lipids - Reducing CVD risk |
Reviews early assessment of cardiovascular risk and consideration of who would benefit from a lipid-lowering drug together with lifestyle changes |
Professional publication - Prescribing Practice Review | Health Professionals | 2011-03-01 00:00:00 |
Reducing CVD risk: lifestyle, statins and ezetimibe |
This pharmacy practice review provides pharmacists with the opportunity to review the optimal use of lipid-modifying medicines in patients at risk of cardiovascular disease |
Professional activity - Pharmacy Practice Review | Health Professionals | 2010-06-10 00:00:00 |
Rosuvastatin (Crestor) for dyslipidaemia |
Reviews use of rosuvastatin for dyslipidaemia, including target LDL-C levels, dosage guidelines, and safety profile. |
Professional publication - NPS RADAR - Review | Health Professionals | 2006-12-01 00:00:00 |
Information on this website is published by NPS — an independent, evidence based, not-for-profit organisation funded by the Australian Government Department of Health and Ageing.
NPS develops its information under the guidance of experts in their field, editorial panels, expert reviewers and consumers. Find out more about how we develop our content.
Date published: 2010-12-17 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
